🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate

Found 29 matching trials

A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma

PHASE2

The purpose of this study is to evaluate the effect of 2 different GP meter...

Status

Recruiting

Location

Research Site

Start Date

2026-04-14

Trial ID

NCT07525375

Treatments Being Tested

GP MDI BFF MDI Placebo MDI

Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study

PHASE4

The goal of this clinical trial is to determine if triple inhaled therapy w...

Status

Completed

Location

Narongkorn Saiphoklang

Start Date

2025-04-01

Trial ID

NCT06905483

Treatments Being Tested

Budesonide/Glycopyrronium/Formoterol (BGF)Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)

A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate

PHASE1

This study is a 2 treatment period, single dose crossover, gamma scintigrap...

Status

Completed

Location

Research Site

Start Date

2018-09-04

Trial ID

NCT03740373

Treatments Being Tested

BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold BGF MDI ((budesonide, glycopyrronium and formoterol fumarate) with 3 s breath hold

Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)

N/A

The aim of the CHOROS ORION study is to describe patients' clinical and sel...

Status

Completed

Location

Research Site

Start Date

2023-06-01

Trial ID

NCT05862545

Treatments Being Tested

BGF (budesonide/glycopyrrolate/formoterol fumarate)

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

PHASE1

The study will assess the Pharmacokinetic (PK) and safety of BGF MDI \[Bude...

Status

Completed

Location

Research Site

Start Date

2022-07-29

Trial ID

NCT05477108

Treatments Being Tested

Treatment A (BGF MDI HFO with oral activated charcoal)Treatment B (BGF MDI HFA with oral activated charcoal)

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

PHASE3

This is a randomized, double-blind, multi-center, parallel-group study to a...

Status

Completed

Location

Research Site

Start Date

2015-06-30

Trial ID

NCT02465567

Treatments Being Tested

BGF MDI 320/14.4/9.6 μg GFF MDI 14.4/9.6 μg BGF MDI 160/14.4/9.6 μg BFF MDI 320/9.6 μg

Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers

PHASE1

This is a Phase I, Randomized, Double-Blind Within Device, Single-Dose, Fou...

Status

Completed

Location

Pearl Therapeutics Study Site

Start Date

2013-11

Trial ID

NCT01980615

Treatments Being Tested

Inhaled BGF (PT010) Dose 1 Inhaled BGF (PT010) Dose 2 Inhaled BGF (PT010) Dose 3 Inhaled GFF (PT003)Inhaled Symbicort Dose 1 Inhaled Symbicort Dose 2

REported Outcomes in COPD With Trixeo in Real worlD in Germany

N/A

Chronic obstructive pulmonary disease (COPD) is characterized by persistent...

Status

Completed

Location

Research Site

Start Date

2022-03-15

Trial ID

NCT05311306

A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer

PHASE1

The primary purpose of this study is to demonstrate the equivalence of bude...

Status

Withdrawn

Location

Multiple Locations

Start Date

2024-10-17

Trial ID

NCT06340581

Treatments Being Tested

Treatment A: BGF MDI HFA Treatment B: BGF MDI HFO Treatment C: BGF MDI HFO AeroChamber Plus Flow-Vu Spacer

Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease

PHASE4

The purpose of this study is to observe the safety and tolerability of Brez...

Status

Recruiting

Location

Research Site

Start Date

2026-01-30

Trial ID

NCT06531798

Treatments Being Tested

Breztri Aerosphere

Previous Next